Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
16.
Ann Endocrinol (Paris) ; 64(3): 202-4, 2003 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12910062

RESUMEN

We report a case of symptomatic topical corticosteroid-induced adrenal insufficiency and diabetes in a 46-yr old HIV 1 positive woman of African descent. Topical Betamethasone dipropionate 0.05%-containing creams were used for the purpose of bleaching over a 2 month period prior to the acute episode. She recovered from her acute onset diabetes with ketosis and adrenal insufficiency a few months after withdrawal of corticosteroids. Despite possible discussion about pathophysiology of diabetes because acute-onset remitting diabetes is not rare in patients of African descent, and diabetes may occur in patients taking anti-retroviral treatments, no other cause of a hypothalamo-pituitary-adrenal axis disorder was found. This case suggests that chronic use of high dose topical corticosteroid containing creams should be ruled out in patients presenting with Hypothalamo-Pituitary-Adrenal hypofunction.


Asunto(s)
Insuficiencia Suprarrenal/inducido químicamente , Antiinflamatorios/efectos adversos , Betametasona/análogos & derivados , Betametasona/efectos adversos , Diabetes Mellitus/inducido químicamente , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Administración Tópica , África del Sur del Sahara/etnología , Femenino , Francia , Glucocorticoides , Humanos , Persona de Mediana Edad
17.
Ann Dermatol Venereol ; 129(6-7): 866-9, 2002.
Artículo en Francés | MEDLINE | ID: mdl-12218913

RESUMEN

PATIENTS AND METHODS: We studied prospectively the feasibility of post exposure prophylaxis against HIV in 93 subjects consulting after sexual exposure at STD Center of Hopital Saint-Louis. Among the 93 subjects, 76 were men (45 homosexual) and 17 women. RESULTS: Delay to consultation was 38 h. Among sexual exposure 90 p. 100 were anal or vaginal intercourse and 10 p. 100 oral intercourse. Fifty percent were unprotected. Seventy-five percent of source subject HIV status was unknown, but controlled negative in 14 p. 100 of cases. Three subjects were infected initially. Seventy-two subjects were treated, with triple regimen, for 30 days without severe adverse event. Twenty-five percent were lost to follow up before the end of treatment, only 54 controlled their serology after the end of treatment (after 1 month: 70 p. 100, after 2 months: 51 p. 100 and after 4-6 months: 13 p. 100). DISCUSSION: This study underlines the difficulty in obtaining clinical and serological control after post exposure prophylaxis, even in a STD Department involved in prevention and counseling.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/prevención & control , Infecciones por VIH/transmisión , Indinavir/uso terapéutico , Lamivudine/uso terapéutico , Nelfinavir/uso terapéutico , Conducta Sexual , Zidovudina/uso terapéutico , Serodiagnóstico del SIDA , Quimioterapia Combinada , Estudios de Factibilidad , Femenino , Infecciones por VIH/sangre , Infecciones por VIH/diagnóstico , Infecciones por VIH/epidemiología , Humanos , Masculino , Paris/epidemiología , Estudios Prospectivos , Conducta Sexual/estadística & datos numéricos , Factores de Tiempo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA